Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.

NCT03944915 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT03944915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03944915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Completed
Start date
August 26, 2019
Completion date
November 1, 2023
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc, hpv-related squamous cell carcinoma, human papilloma virus, squamous cell carcinoma, squamous cell carcinoma of the head and neck